Skip to Main Content

So here’s the big question for Hal Barron as he departs GlaxoSmithKline: Did he accomplish his mission?

The mission, put simply, was to turn around GSK’s labs when he was hired as chief scientific officer four years ago. At the time, the British drug maker was struggling to develop new medicines, its pipeline not exactly flush.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment